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What is already known about this subject {#bcp14071-sec-0006}
========================================

An increase in the number of direct oral anticoagulant drug (DOAC) users with a diagnosis of nonvalvular atrial fibrillation (NVAF) has been reported since their marketing in several national/regional studies in Europe, but no cross‐national comparison is available.The characteristics of DOAC users related to NVAF have been described but concomitant use of potentially interacting drugs is rarely reported. DOAC users are usually younger than 75 years, male and 20% of DOAC users with NVAF receive dose adjustment related to renal function.

What this study adds {#bcp14071-sec-0007}
====================

Overall DOAC incidences varied from 1.93 to 2.60 and 0.11 to 8.71 users/10 000 (2011--2015) for dabigatran and rivaroxaban, respectively, and from 0.01 to 8.12 users/10 000 (2012--2015) for apixaban.In 2015, the new user DOAC incidence ranged from 9 to 28/10 000 inhabitants 18 years and older in SIDIAP (Catalonia, Spain) and DNR (Denmark) databases respectively, this being higher in men than in women and in those older than 75 years.Concomitant use of contraindicated or potentially interacting drugs varied between 16.4% (SIDIAP) and 70.5% (EGB). Dose adjustment related to age or renal function varied from 4.6% (BIFAP, Spain) to 15.6% (EGB, France).

1. INTRODUCTION {#bcp14071-sec-0008}
===============

Patients with atrial fibrillation have long been treated with vitamin K antagonists for the prevention of cerebral embolism. The newer direct oral anticoagulants (DOACs) have been approved by the European Union since 2008. The first was dabigatran (2008), a <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362> inhibitor; this was followed by rivaroxaban (2008), apixaban (2011) and edoxaban (2015), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359> inhibitors. The first approval for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) was for dabigatran in 2011 (Table [S1](#bcp14071-supitem-0001){ref-type="supplementary-material"}). DOACs are currently recommended by the European Society of Cardiology as first‐line anticoagulant treatment in NVAF, without mitral stenosis or mechanical heart valves.[1](#bcp14071-bib-0001){ref-type="ref"}

The incidence of NVAF is estimated to be 3% in adults aged 20 or older, increasing with age,[2](#bcp14071-bib-0002){ref-type="ref"}, [3](#bcp14071-bib-0003){ref-type="ref"} with incidence of 12% in females and 14% in males aged over 75 years.[3](#bcp14071-bib-0003){ref-type="ref"} Atrial fibrillation is associated with increased cardiovascular morbidity, such as heart failure and stroke.[4](#bcp14071-bib-0004){ref-type="ref"}, [5](#bcp14071-bib-0005){ref-type="ref"} Clinical trials have shown that both vitamin K antagonists and DOACs reduce stroke and mortality in AF patients.[5](#bcp14071-bib-0005){ref-type="ref"}, [6](#bcp14071-bib-0006){ref-type="ref"} Utilization of DOACs for stroke prevention in NVAF and their effectiveness and safety in clinical practice have been assessed in several European countries.[7](#bcp14071-bib-0007){ref-type="ref"}, [8](#bcp14071-bib-0008){ref-type="ref"}, [9](#bcp14071-bib-0009){ref-type="ref"}, [10](#bcp14071-bib-0010){ref-type="ref"}, [11](#bcp14071-bib-0011){ref-type="ref"}, [12](#bcp14071-bib-0012){ref-type="ref"}, [13](#bcp14071-bib-0013){ref-type="ref"} However, little is known about their use beyond clinical trial conditions, especially in patients with hepatic or renal impairment. Findings from 2 studies from USA and Australia showed that inappropriate dosing occurred among patients with renal failure, and there is still uncertainty about appropriate dosing in these patients.[14](#bcp14071-bib-0014){ref-type="ref"}, [15](#bcp14071-bib-0015){ref-type="ref"} In addition, the very elderly, who may be at increased risk of adverse effects with inappropriate DOAC use, are poorly represented in clinical trials.[16](#bcp14071-bib-0016){ref-type="ref"}, [17](#bcp14071-bib-0017){ref-type="ref"}

This cross‐national comparison drug utilization study, using longitudinal data from 8 electronic health care databases in 6 European countries, uses a common protocol to characterize DOAC users in a real‐world setting in order to establish the effectiveness of existing risk minimization measures and their appropriateness for the future. Its objectives are to assess incidence of use and user characteristics, including concomitant exposure to potentially interacting medicines and rates of dose adjustment related to age or renal impairment.

2. METHODS {#bcp14071-sec-0009}
==========

2.1. Data sources {#bcp14071-sec-0010}
-----------------

We conducted a longitudinal drug utilization study in 6 countries between January 2008 and December 2015. Data were retrieved from the following 8 databases: (i) the Dutch Mondriaan project, which includes the Julius General Practitioner Network (JHN) database[18](#bcp14071-bib-0018){ref-type="ref"}; (ii) the Danish National Registries (DNR), which includes the Danish National Patient Register, Danish National Prescription Registry and Danish Civil Registration System[19](#bcp14071-bib-0019){ref-type="ref"}, [20](#bcp14071-bib-0020){ref-type="ref"}, [21](#bcp14071-bib-0021){ref-type="ref"}; (iii) the AOK Nordwest database[22](#bcp14071-bib-0022){ref-type="ref"}, [23](#bcp14071-bib-0023){ref-type="ref"}, Germany; (iv) the Bavarian Association of Statutory Health Insurance Physicians database, referred to here as Bavarian CD, Germany[24](#bcp14071-bib-0024){ref-type="ref"}; (v) the *Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria* (BIFAP), Spain[25](#bcp14071-bib-0025){ref-type="ref"}; (vi) the Information System for the Development of Research in Primary Care (SIDIAP), Catalonia, Spain[26](#bcp14071-bib-0026){ref-type="ref"}; (vii) the Clinical Practice Research Datalink (CPRD), UK[27](#bcp14071-bib-0027){ref-type="ref"}, [28](#bcp14071-bib-0028){ref-type="ref"}; (viii) The *Echantillon Généraliste de Bénéficiaires* (EGB), France.[29](#bcp14071-bib-0029){ref-type="ref"} The databases characteristics are described in Table [1](#bcp14071-tbl-0001){ref-type="table"}.

###### 

Database characteristics

                                                            Mondriaan                                           Danish National Registries                   AOK Nordwest                                                                       Bavarian Claims                                                  BIFAP                                                SIDIAP                                               CPRD                                        EGB
  --------------------------------------------------------- --------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Source population (million inhabitants)                   0.4                                                 5.5                                          2.7                                                                                10.5                                                             7.5                                                  5.8                                                  12.5                                        0.7 
  Population coverage                                       3%                                                  100%                                         24%                                                                                84%                                                              16.4%[a](#bcp14071-note-0003){ref-type="fn"}         80%                                                  8%[a](#bcp14071-note-0003){ref-type="fn"}   Representative sample of *Système National d\'Informations Inter‐Régimes de l\'Assurance Maladie* \[98.8%\]
  Year(s) covered for this study                            2012--2015[b](#bcp14071-note-0004){ref-type="fn"}   2008--2015                                   2008--2015                                                                         2008--2015                                                       2008--2015                                           2009--2015                                           2008--2015                                  2013--2015[c](#bcp14071-note-0005){ref-type="fn"}
  Type of database[d](#bcp14071-note-0006){ref-type="fn"}   GP prescribing data and pharmacy dispensing data.   Dispensing data from community pharmacies.   Claims database including data for dispensed reimbursed drugs                      Claims database including data for dispensed reimbursed drugs.   General practice prescribing data/reimbursed data.   General practice prescribing data/reimbursed data.   General practice prescribing data.          Claims database including dispensed reimbursed data.
  Data available since                                      1991                                                1994                                         2007                                                                               2008                                                             2001                                                 2006                                                 1987                                        2004
  Demographic variables available                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Date of registration                                      Yes                                                 Yes                                          Yes                                                                                Yes (first consultation)                                         Yes                                                  Yes                                                  Yes                                         Yes
  Date of transferring out                                  Yes                                                 Yes                                          Yes                                                                                Yes (last consultation)                                          Yes                                                  Yes                                                  Yes                                         Yes
  Date of birth                                             DD‐MM‐YY                                            MM‐YY                                        MM‐YY                                                                              MM‐YY                                                            MM‐YY                                                MM‐YY                                                MM‐YY                                       YY
  Sex                                                       Yes                                                 Yes                                          Yes                                                                                Yes                                                              Yes                                                  Yes                                                  Yes                                         Yes
  Drug information available                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Active international coding                               ATC                                                 ATC                                          ATC                                                                                ATC                                                              ATC                                                  ATC                                                  BNF                                         ATC
  Product coding                                            HPK                                                 Nordic article number                        PZN                                                                                PZN                                                              CNF                                                  Yes[e](#bcp14071-note-0007){ref-type="fn"}           Product code                                CIP‐13
  Date of prescribing/dispensing                            Yes                                                 Yes                                          Primary care sector: Yes                                                           Yes (for each prescription the quarter is documented)            Yes                                                  Yes[f](#bcp14071-note-0008){ref-type="fn"}           Yes                                         Yes
  Primary care sector                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  GP                                                        Yes                                                 Yes                                          Yes                                                                                Yes                                                              Yes                                                  Yes                                                  Yes                                         Yes
  Specialist                                                No                                                  Yes                                          Yes                                                                                Yes                                                              No                                                   No                                                   No                                          Yes
  Secondary care sector                                     No                                                  No                                           Yes---only for a few selected (expensive) compounds, but no (D)OAC prescriptions   No                                                               No                                                   No                                                   No                                          Yes---only for a few selected (expensive) compounds, but no (D)OAC prescriptions
  Quantity prescribed/dispensed                             Yes                                                 Yes                                          Yes (package size)                                                                 Yes (package size)                                               Yes                                                  Yes[g](#bcp14071-note-0009){ref-type="fn"}           Yes                                         Yes
  Dosing regimen                                            No                                                  No                                           No                                                                                 No                                                               Yes                                                  Yes[h](#bcp14071-note-0010){ref-type="fn"}           Yes                                         No
  Outcome information                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Outpatient primary care diagnosis                         ICPC                                                No                                           ICD‐10‐GM (quarterly base)                                                         ICD‐10‐GM (for each diagnosis the quarter is documented)         ICPC‐2, ICD‐9                                        ICD‐10                                               ICD‐9, ICD‐10                               ICD‐10
  Hospital discharge diagnosis                              No                                                  ICD‐8, ICD‐10                                ICD‐10‐GM                                                                          No                                                               No                                                   No[i](#bcp14071-note-0011){ref-type="fn"}            ICD‐9, ICD‐10                               ICD‐10
  Laboratory tests                                          Yes                                                 No                                           No                                                                                 No                                                               Yes (as requested by GP)                             Yes                                                  Yes                                         No
  Mortality                                                 Yes                                                 Yes                                          No (incompletely recorded, e.g. no follow‐up for patients leaving the AOK)         No                                                               Yes (no cause of death)                              Yes (no cause of death)                              Yes                                         Yes (no cause of death)

Representative of general population.

No data on DOAC) use available until 2012. DOACs were not prescribed by general practitioners in the Netherlands before 2012.

No data on DOAC use available until 2013.

Prescribing databases: collect information on prescribed drugs by GP; Reimbursement databases: collect information on dispensed drugs funded by Health Care Services; Dispensing databases: collect all dispensation of prescription drugs regardless of the drug\'s reimbursement status *(Ref. Eriksson E and Ibañez L. Secondary data sources for drug utilization research. In Elseviers M et al. Drug utilization research. Methods and applications. John Willey and Sons, 2016)*.

Registered but not available for research due to confidentiality reasons;

For dispensing: MM/YY;

Number of reimbursed packages;

Only in prescribing data;

Available for 28% of included population.

(D)OAC, (direct) oral anticoagulant; GP, general practitioner; ATC, Anatomical Therapeutic Classification; BNF, British National Formulary; HPK, Handels Product Code; PZN, Pharma Zentral Nummer; CNF, Código Nacional Farmacéutico; ICD (International Classification of Diseases; ICD‐10‐GM: ICD ‐10‐German Modification), ICPC (International Classification of Primary Care).

2.2. Study population {#bcp14071-sec-0011}
---------------------

The study population was defined as all new users (age ≥18 years) of the DOACs of interest (dabigatran, rivaroxaban, apixaban). Only those patients with a diagnosis of NVAF (see codes in supplementary material, Table [S2](#bcp14071-supitem-0001){ref-type="supplementary-material"}) were included. A common protocol was applied for data extraction and analysis (EU PASS Register No: 16014) for each database.[30](#bcp14071-bib-0030){ref-type="ref"} Results were blinded to each database lead until the analysis was completed.

New users were defined as patients initiating DOAC during the study period without any use of DOAC for at least 365 days prior to the index date (date of first DOAC prescription). Flow charts for patient inclusion for each database are shown in Figure [S1](#bcp14071-supitem-0002){ref-type="supplementary-material"}.

Patients registered in the database \<1 year (365 days) before the index date and patients with a history of valvular atrial fibrillation on index date or any time prior to initiating DOACs were excluded. Follow‐up of each patient was until therapy switch, discontinuation or end of study, whichever came first. Switchers were defined as patients with a subsequent prescription of another type of (D)OAC, within the first treatment episode. Discontinuers were defined as patients who did not receive subsequent DOACs within 30 days following the theoretical end date of the prior DOAC.

As DOACs can be prescribed for indications other than NVAF, a sensitivity analysis was performed excluding patients with multiple potential DOAC indications in a ± 3 month period around the first DOAC prescription.

2.3. Ethical approval {#bcp14071-sec-0012}
---------------------

Participants in each country had study approval from the corresponding data owners. No other requirement was required since anonymized data were used. Additionally, the study protocol was revised and approved by an internal European Medicines Agency expert panel.

2.4. Outcomes {#bcp14071-sec-0013}
-------------

The main outcome was assessing incidence of DOAC use in patients with NVAF during the study period.

Annual period incidences are estimated and defined as the number of new users during the year of interest, divided by the total number of patients in the database at midyear (1 July).

Secondary aims were to assess concomitant use of interacting drugs, defined as any prescription of a potentially interacting medicinal product as indicated in the Summary of Product Characteristics (SmPC) during the first DOAC treatment episode of each patient. A list of the concomitant interacting drugs considered in the SmPC is given in eSupplementary Material (Table [S3](#bcp14071-supitem-0001){ref-type="supplementary-material"}). A treatment episode was defined as series of prescriptions for a DOAC, independent of dose changes, considering a gap of up to 30 days, constructed according to the method of Gardarsdottir et al.[31](#bcp14071-bib-0031){ref-type="ref"}

Furthermore, the occurrence of dose adjustment, defined as changing from 1 tablet strength to another strength of the same active substance, was assessed during the first treatment episode.

2.5. Analysis {#bcp14071-sec-0014}
-------------

The analysis is descriptive and stratified by database, individual DOAC, age group (\<75, 75--79, ≥80 years), sex and calendar year.

The baseline characteristics (demographics \[sex, age\]), comorbidities, chronic kidney disease (CKD), renal function, laboratory data when available, hepatic impairment, previous major haemorrhagic episodes, previous cardiovascular events (see codes in Table [S4](#bcp14071-supitem-0001){ref-type="supplementary-material"}) and concomitant exposure to potentially interacting medicines of DOAC users are presented as absolute number and percentages for each variable.

For all databases, annual period incidences, with direct standardisation by age and sex was performed based on the European standard population corresponding to each year analysed.[32](#bcp14071-bib-0032){ref-type="ref"} An incidence percentage change in DOAC users with NVAF is given in comparison to the first calendar year when NVAF became an approved indication for use (2012 for dabigatran and rivaroxaban, 2013 for apixaban). However, in the EGB database, DOAC percentage change was assessed for 2013--2014 since these are the calendar years with complete information. In addition, a percentage change of the standardized incidence, weighted by the database populations, was calculated from the first to the last calendar year of use.

Percentage of new DOAC users exposed to potentially interacting medication is expressed as the absolute number and percentage of the total DOAC users. Dose adjustment is expressed as the percentage of patients with adjusted dosage following the requirements of the SmPC and presented either related to change in age or renal function, as indicated in the SmPC.

2.6. Nomenclature of targets and ligands {#bcp14071-sec-0015}
----------------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY,[33](#bcp14071-bib-0033){ref-type="ref"} and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18.[34](#bcp14071-bib-0034){ref-type="ref"}

3. RESULTS {#bcp14071-sec-0016}
==========

3.1. New users {#bcp14071-sec-0017}
--------------

A total of 186 405 new DOAC users (age ≥18 years) with NVAF were identified during the study period.

Of all new DOAC users, 91 804 (49%), 52 495 (28%) and 42 106 (22%) received rivaroxaban, dabigatran and apixaban, respectively.

3.2. Baseline characteristics {#bcp14071-sec-0018}
-----------------------------

Most of the users were age 75 years or older (48.8% in Mondriaan to 60.8% in BIFAP). The mean age ranged from 69.3; SD 11.3 (Mondriaan) to 75.7; SD 10.4 years (BIFAP) (Table [2](#bcp14071-tbl-0002){ref-type="table"}).

###### 

Baseline characteristics for all direct oral anticoagulant new users

                                                         Mondriaan   Danish National Registries   AOK Nordwest   Bavarian Claims   BIFAP    SIDIAP   CPRD     EGB                                                     
  ------------------------------------------------------ ----------- ---------------------------- -------------- ----------------- -------- -------- -------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  Female                                                 189         41.1                         20 331         45.3              11 650   53.6     44 070   52.3   6755   47.7   5598   46.8   3049   44.0   867    42.9
  Male                                                   271         58.9                         24 545         54.7              10 068   46.4     40 206   47.7   7406   52.3   6364   53.2   3882   56.0   1154   57.1
  Age (y), mean (SD)                                     69.3        11.3                         73.9           10.9              74.5     11.0     74.5     11.0   75.7   10.4   74.6   10.9   74.7   11.0   72.8   12.0
  18--74                                                 310         67.4                         22 977         51.2              8795     40.5     36 658   43.5   5558   39.2   5165   43.2   3110   44.9   995    49.2
  75--79                                                 61          13.3                         7258           16.2              4785     22.0     17 979   21.3   2647   18.7   2249   18,8   1300   18.7   353    17.5
  ≥80                                                    89          19.3                         14 641         32.6              8138     37.5     29 639   35.2   5956   42.1   4548   38,0   2521   36.4   673    33.3
  Comorbidities                                          143         31.1                         29 161         66.7              18 952   87.3     73 488   87.2   6865   48.5   6437   53.8   4337   62.6   1042   51.6
  Hepatic impairment                                     0           0                            969            2.1               3119     14.4     14 845   17.6   33     0.2    27     0.2    3      0.0    52     2.6
  Chronic kidney disease (by diagnosis codes)            0           0                            2055           4.6               4377     20.1     20 287   24.1   226    1.6    509    4.3    309    4.5    58     2.9
  Previous major haemorrhagic episodes                   28          6.1                          1642           3.6               2634     12.1     13 745   16.3   532    3.8    500    4.2    177    2.6    60     3.0
  Haemorrhagic stroke/intracranial bleeding              21          4.6                          231            0.5               382      1.7      2087     2.5    37     0.3    66     0.5    15     0.2    14     0.7
  Extracranial or unclassified major bleeding            0           0                            833            1.8               1824     8.4      8182     9.7    326    2.3    300    2.5    114    1.6    34     1.7
  Gastrointestinal bleeding                              7           1.5                          536            1.2               903      4.1      4036     4.8    168    1.2    116    1.0    49     0.7    14     0.7
  Traumatic intracranial bleeding                        0           0                            136            0.3               40       0.2      671      0.8    10     0.1    30     0.2    0      0      4      0.2
  Previous cardiovascular events                         117         25.4                         29 959         65.0              17 998   82.9     64 618   76.7   5330   37.6   5653   47.3   3107   44.8   996    49.3
  Coronary heart disease: Angina/myocardial infarction   68          14.8                         10 584         23.6              12 439   57.3     46 062   54.6   1932   13.6   2156   18.0   1286   18.6   376    18.6
  Congestive heart failure                               41          8.9                          20 134         44.9              9708     44.7     39 363   46.7   1921   13.6   2278   19.0   755    10.9   690    34.1
  Peripheral arterial disease                            0           0                            1768           3.9               4876     22.4     16 782   19.1   531    3.7    784    6.5    308    4.4    0      0
  Stroke/transient ischaemic attack                      26          5.7                          9555           21.3              6098     28.1     22 789   27.0   2099   14.8   2418   20.2   1474   21.3   208    10.3
  Deep vein thrombosis/pulmonary embolism                0           0                            2121           4.7               1114     5.1      5247     6.2    58     0.4    68     0.6    236    3.4    21     1.0
  Aortic plaque                                          4           0.9                          140            0.3               961      4.4      4163     4.9    952    6.7    9      0.1    11     0.2    121    6.0

Users were most frequently male (range 52.3--58.9%), except in the AOK and Bavarian CD databases where the opposite was found (range 46.4--47.7%).

The proportion of patients with comorbidities ranged from 31.1% (Mondriaan) to 87.3% (AOK). Most frequent were previous cardiovascular events (25.4% in Mondriaan to 82.9 and 76.7% in AOK and Bavarian CD, respectively).

The number of patients with acute or chronic kidney disease, identified through diagnosis codes, ranged from 0% in the Mondriaan to 24.1% in the Bavarian CD databases. Assessment of laboratory values with moderately reduced kidney function (Mondriaan, BIFAP, SIDIAP and CPRD) showed a range from 3.0% (Mondriaan) to 22.6% (CPRD). DOAC users with severely or very severely reduced renal function were very uncommon in these databases. However, the proportion of unregistered information was usually high (range: 3.4% in CPRD to 77.9% in BIFAP; Table [S5](#bcp14071-supitem-0001){ref-type="supplementary-material"}).

3.3. Incidence {#bcp14071-sec-0019}
--------------

During this period, overall DOAC incidence increased (Figure [1](#bcp14071-fig-0001){ref-type="fig"}). Standardized incidences varied from 1.93--2.60 and 0.11--8.71 users/10 000 (2011--2015) for dabigatran and rivaroxaban, respectively, and from 0.01--8.12 users/10 000 (2012--2015) for apixaban (Table [3](#bcp14071-tbl-0003){ref-type="table"}). Apixaban displayed the highest standardized incidence percentage change from the first year of use following approval in NVAF to the final year studied (543.2%), followed by rivaroxaban (100.2%; Figure [1](#bcp14071-fig-0001){ref-type="fig"}). This was mainly driven by a sharp increase in EGB. The standardized percentage incidence change for this first calendar year compared to the previous year was maximum in EGB (10 550.0%) and minimum in Bavarian CD (218.6%); values comparing for 2014 and 2015 were maximum in Mondriaan (868.5%) and minimum in SIDIAP (35.1%).The percentage for rivaroxaban increased in all databases during the first calendar year of use, except in EGB, with the greatest increase in CPRD (120.9%); a decrease was seen in the 2 German databases and EGB in 2014--2015 (Table [4](#bcp14071-tbl-0004){ref-type="table"}).

![Distribution of the total standardized incidence by individual direct oral anticoagulant (DOAC; 2011--2015)](BCP-85-2524-g001){#bcp14071-fig-0001}

###### 

Standardized incidences by individual direct oral anticoagulant (DOAC) per year (new users per 10 000 people)

  DOAC          2010   2011   2012   2013   2014   2015
  ------------- ------ ------ ------ ------ ------ ------
  Dabigatran    0.10   2.60   5.33   4.98   3.49   1.93
  Rivaroxaban   0.06   0.11   4.35   8.77   8.85   8.71
  Apixaban      0.00   0.00   0.01   1.26   4.99   8.12

###### 

Standardized incidence percentage change in direct oral anticoagulant new users with a diagnosis of nonvalvular atrial fibrillation (NVAF) in the time periods for the first and last calendar year of use after NVAF indication approval (2012--2015)

                    Incidence percentage change for the first calendar year of use after NVAF approval[a](#bcp14071-note-0013){ref-type="fn"}   Incidence percentage change 2014--2015   Incidence percentage change from the first calendar year of use to 2015                                                  
  ----------------- --------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------- --------- -------- -------- -------- --------- -----------
  Mondriaan         −22.93                                                                                                                      833.97                                   2397.26                                                                   32.54     868.50   63.36    11.52    8945.51   21 048.75
  NRD               −4.58                                                                                                                       268.27                                   266.94                                                                    −63.54    60.94    42.41    −73.56   492.68    418.75
  AOK Nordwest      −8.04                                                                                                                       313.13                                   98.40                                                                     −35.54    80.03    −12.89   −66.09   643.75    74.60
  Bavarian Claims   −18.43                                                                                                                      218.61                                   67.96                                                                     ‐ 41.56   47.54    −24.18   −74.38   370.09    14.99
  BIFAP             −15.02                                                                                                                      712.82                                   227.42                                                                    −6.08     52.37    12.50    −32.81   1138.46   320.97
  SIDIAP            −7.13                                                                                                                       462.60                                   247.88                                                                    −5.80     35.13    27.75    −26.43   660.23    480.62
  CPRD              80.98                                                                                                                       774.46                                   732.89                                                                    3.55      180.91   120.90   88.31    2356.46   4902.39
  EGB               −69.55                                                                                                                      10 550.0                                 −32.33                                                                    −56.37    162.44   −16.21   −86.72   27850.0   −43.30

Data for dabigatran and rivaroxaban are calculated for 2012--2013. Data for apixaban are calculated for 2013--2014 in all databases. Data for each DOAC are calculated for 2013--2014 in EGB.

The standardized figures show that the incidence of dabigatran clearly increased in most databases from 2010 to 2012, with the highest value in the DNR (15.5 new users per 10 000). The CPRD and Mondriaan figures increased slightly at the end of the study period. The apixaban standardized incidence increased across 2013--2015 in all databases. The maximum value was observed in the DNR database in 2015 (13.6 new users per 10 000). The rivaroxaban standardized incidence increased over time in all databases since its arrival on the market, except in EGB; however, it started to decrease in Bavarian CD in 2014 and AOK in 2015. The Bavarian CD database presented the highest rivaroxaban standardized incidence in 2013 (17.5 new users per 10 000). Rivaroxaban showed the highest annual incidence values in the 2012--2015 period in all databases except in the DNR (Figure [2](#bcp14071-fig-0002){ref-type="fig"}; Tables [S6--S9](#bcp14071-supitem-0001){ref-type="supplementary-material"}). The DOAC incidence increased in males and females across the study period in most databases, especially in those over 75 years, whose incidences were higher than those, men and women, younger than 75 years (Figures [S2--S4](#bcp14071-supitem-0002){ref-type="supplementary-material"}).

![Standardized incidences by individual direct oral anticoagulant in each database](BCP-85-2524-g002){#bcp14071-fig-0002}

In 2015, the incidence of DOAC use ranged from 8.6 per 10 000 in SIDIAP to 27.6 per 10 000 in DNR (Table [S6](#bcp14071-supitem-0001){ref-type="supplementary-material"}), with a higher incidence in men than in women.

Figure [3](#bcp14071-fig-0003){ref-type="fig"} shows the incidence data for all DOACs, per database and per year, for the whole study period.

![Standardized and crude incidence for all direct oral anticoagulants per year and database](BCP-85-2524-g003){#bcp14071-fig-0003}

3.4. Concomitant use of potentially interacting drugs {#bcp14071-sec-0020}
-----------------------------------------------------

The proportion of patients who received an interacting drug during the first treatment episode ranged from 16.4% (SIDIAP) to 70.5% (EGB). Concomitant use of contraindicated anticoagulants varied between 0.4% (CPRD) and 24.3% (EGB). Nonsteroidal anti‐inflammatory drugs (NSAIDs) varied from 4.3% (Mondriaan) to 26.0% (Bavarian CD) and antiplatelet drugs from 1% (SIDIAP) to 18.1% (EGB). The most frequent interacting drugs were heparins in AOK, BIFAP and Bavarian CD (8.4, 10.4 and 12.1%, respectively), amiodarone in SIDIAP, DNR and EGB databases (5.7, 6.2 and 42.2%, respectively) and verapamil in Mondriaan (4.1%; Table [5](#bcp14071-tbl-0005){ref-type="table"}).

###### 

Concomitant treatment during the first treatment episode

                                                                          Mondriaan               Danish National Registries   AOK Nordwest        Bavarian Claims   BIFAP           SIDIAP   CPRD            EGB                                                                                                            
  ----------------------------------------------------------------------- ----------------------- ---------------------------- ------------------- ----------------- --------------- -------- --------------- ------ --------------- ------ --------------- ------ ----------------------- ------ -------------------------- ------
  CONCOMITANT MEDICATION (potential interacting medicine products)        94                      20.4                         15 765              37.8              10 585          48.7     44 394          52.7   6781            47.9   1963            16.4   1785                    25.8   1425                       70.5
  Concomitant treatment with any other anticoagulants (contraindicated)   21                      4.6                          446                 1.1               3730            17.2     17 153          20.4   1425            10.1   355             3.0    29                      0.4    492                        24.3
  Most frequent drug                                                      Vitamin K antagonists   3.9                          Vit K antagonists   0.6               Heparin group   8.4      Heparin group   12.0   Heparin group   10.4   Heparin group   2.9    Vitamin K antagonists   0.4    Heparin group              12.2
  Platelet aggregation inhibitors excl. Heparin                           23                      5.0                          6455                14.4              2140            9.9      9298            11     1859            13.1   123             1.0    849                     12.2   365                        18.1
  Strong CYP3A4 and/or P‐gp inhibitor comedication                        0                       0.0                          0.5                 0.3               329             1.5      1746            2.0    282             2.0    107             0.9    29                      0.4    3                          0.1
  Most frequent drug                                                      NA                      NA                           Dronedarone         0.3               Dronedarone     1.3      Dronedarone     1.9    Dronedarone     1.6    Dronedarone     0.8    Dronedarone             0.4    Cyclosporine               0.1
  Not strong CYP3A4 and/or P‐gp inhibitors                                30                      6.5                          5473                12.2              2203            10.1     8172            9.7    1592            11.2   712             5.9    623                     9.0    900                        44.5
  Most frequent drug                                                      Verapamil               4.1                          Amiodarone          6.2               Amiodarone      6.7      Amiodarone      6.5    Amiodarone      8.8    Amiodarone      5.7    Amiodarone              6.4    Amiodarone                 42.2
  CYP3A4 and/or P‐gp inducers                                             1                       0.2                          194                 0.4               189             0.9      556             0.7    80              0.5    26              0.2    36                      0.5    5                          0.2
  Most frequent drug                                                      NA                      NA                           Carbamazepine       0.3               Carbamazepine   0.7      Carbamazepine   0.5    Carbamazepine   0.2    Rifampicin      0.1    Phenytoin               0.3    Rifampicin/ Carbamzepine   0.1%
  Transporter interaction: CYP3A4 and/or P‐gp                             8                       1.7                          456                 1.0               123             0.6      160             0.2    139             0.1    58              0.5    10                      0.1    21                         1.0
  Most frequent drug                                                      Naproxen                1.3                          Fluconazole         0.7               Naproxen        0.3      Naproxen        0.1    Naproxen        0.5    Naproxen        0.3    Naproxen                0.2    Fluconazole                0.6
  Nonsteroidal anti‐inflammatory drug                                     20                      4.3                          5878                13.1              5319            24.5     21935           26.0   3337            23.6   696             5.8    313                     4.5    308                        15.2
  Other drugs (only for dabigatran)                                       9                       2.0                          2704                6.0               361             1.7      1417            1.7    507             3.6    257             2.1    700                     10.1   47                         2.3
  Selective serotonin reuptake inhibitors                                 3                       0.7                          2380                5.3               304             1.4      1145            1.4    411             2.9    210             1.8    629                     9.1    39                         1.9
  Serotonin‐norepinephrine reuptake inhibitors                            6                       1.3                          406                 0.9               63              0.3      346             0.4    126             0.9    64              0.5    83                      1,2    10                         0.5

P‐gp, P‐glycoprotein.

3.5. Dose adjustment {#bcp14071-sec-0021}
--------------------

The information on dose adjustment was available in BIFAP, SIDIAP, CPRD and EGB, varying from 4.6% in BIFAP to 15.6% in EGB. The proportion of dose adjustments related to changes in renal function or age was \<1% in the 3 databases where this information was available (BIFAP, SIDIAP and CPRD). In the Mondriaan database there were no dose changes recorded. DNR, AOK and Bavarian CD databases do not have this information registered (Table [S5](#bcp14071-supitem-0001){ref-type="supplementary-material"}).

3.6. Sensitivity analysis {#bcp14071-sec-0022}
-------------------------

Results from the main analysis were compared with results from patients with only NVAF diagnosis. The total number of patients treated with DOACs decreased slightly, but the proportions of the individual DOAC were stable.

Regarding renal function at baseline and dose adjustment, the numbers were quite similar. The percentage of concomitant interacting medications increased in SIDIAP database both for all DOACs and individual DOACs. The percentage of previous cardiovascular events was lower for all DOACs across all databases and the overall percentage of previous haemorrhagic events was similar (Tables [S10--S12](#bcp14071-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#bcp14071-sec-0023}
=============

Using a common protocol, we assessed the incidence of DOAC use during 2009--2015 and the characteristics of 186,405 users from 8 health care databases in 6 European countries (2008--2015). To our knowledge this is the first cross‐national drug utilization study providing the incidence of DOAC use in NVAF patients at a national/regional level, across several European countries. Only a few, single country European studies with similar inclusion criteria have been published, which only provide number of DOAC users rather than incidence figures.[10](#bcp14071-bib-0010){ref-type="ref"}, [12](#bcp14071-bib-0012){ref-type="ref"}, [35](#bcp14071-bib-0035){ref-type="ref"}, [36](#bcp14071-bib-0036){ref-type="ref"}

During the study period, the overall incidence of DOAC user increased, except in the EGB database; the individual DOAC with the highest increase was apixaban followed by rivaroxaban. The largest incidence increase was for apixaban in the EGB. It was maximum for apixaban in the first calendar year of use in EGB (10 550.0) and minimum in Bavarian (218.6) while the values for 2014--2015 were maximum in Mondriaan (868.5) and minimum in SIDIAP (35.1). The striking increase for apixaban in EGB is due to the fact that its use was very low in 2013. In 2015, the incidence of DOAC use ranged from 8.7 per 10 000 in SIDIAP to 27.6 per 10 000 in DNR, with a higher incidence in men and in those older than 75 years.

The differences in incidence across the databases might be explained by the high proportion of previous cardiovascular events in AOK, Bavarian CD and DNR databases (82.9, 76.7 and 65.0%, respectively), which may result in higher incidence of NVAF in these populations. These results correlate well with the distribution of hospital discharges for cardiovascular and cerebrovascular diseases in these countries.[37](#bcp14071-bib-0037){ref-type="ref"}

Furthermore, differences in incidence could arise from the characteristics of the databases such as: prescription *vs* dispensing databases (DOACs prescribed are not necessarily dispensed), inclusion of prescriptions from specialists (although we do not expect differences in the management of NVAF between primary and specialist care since the European guidelines do not differentiate), population coverage (DNR is the only national database), different prescribing patterns in different countries, health services characteristics and their reimbursement policies, publication of guidelines (local or European), media and marketing policies.[9](#bcp14071-bib-0009){ref-type="ref"}, [38](#bcp14071-bib-0038){ref-type="ref"}

Several national/regional studies have reported increases in the number of DOAC users, despite the NVAF population used differing from ours.[9](#bcp14071-bib-0009){ref-type="ref"}, [10](#bcp14071-bib-0010){ref-type="ref"}, [39](#bcp14071-bib-0039){ref-type="ref"}, [40](#bcp14071-bib-0040){ref-type="ref"} The incidence increased in both the males and females across the study period in most databases. More specifically, incidence was higher in males than in females, since NVAF is more common in men.[10](#bcp14071-bib-0010){ref-type="ref"}, [35](#bcp14071-bib-0035){ref-type="ref"}, [41](#bcp14071-bib-0041){ref-type="ref"}, [42](#bcp14071-bib-0042){ref-type="ref"}

4.1. Incidence of individual DOACs {#bcp14071-sec-0024}
----------------------------------

Overall, rivaroxaban presented the highest incidence figures, except in the DNR, followed by apixaban and dabigatran. The initial steep increase in rivaroxaban and apixaban incidence observed in most of the databases appeared by the end of 2011 and 2012 respectively, after approval for stroke prevention.[43](#bcp14071-bib-0043){ref-type="ref"} This sharp increase was not observed for dabigatran as clearly in any of the databases. Other studies have shown a steep increase in users for each DOAC after their marketing.[36](#bcp14071-bib-0036){ref-type="ref"}, [39](#bcp14071-bib-0039){ref-type="ref"}

4.2. Demographic characteristics {#bcp14071-sec-0025}
--------------------------------

The mean age of our study population reflected other European studies on users of DOAC with NVAF, despite varying inclusion criteria.[10](#bcp14071-bib-0010){ref-type="ref"}, [12](#bcp14071-bib-0012){ref-type="ref"}, [35](#bcp14071-bib-0035){ref-type="ref"}, [36](#bcp14071-bib-0036){ref-type="ref"}, [39](#bcp14071-bib-0039){ref-type="ref"}, [41](#bcp14071-bib-0041){ref-type="ref"}, [44](#bcp14071-bib-0044){ref-type="ref"} In line with other studies, we found that most of the users were older than 75 years, except in Mondriaan and DNR databases.[10](#bcp14071-bib-0010){ref-type="ref"}, [12](#bcp14071-bib-0012){ref-type="ref"}, [40](#bcp14071-bib-0040){ref-type="ref"}

A higher proportion of males was observed in all except the German databases, similarly to other published studies.[10](#bcp14071-bib-0010){ref-type="ref"}, [12](#bcp14071-bib-0012){ref-type="ref"}, [35](#bcp14071-bib-0035){ref-type="ref"}, [36](#bcp14071-bib-0036){ref-type="ref"}, [41](#bcp14071-bib-0041){ref-type="ref"} The larger proportion of women in the German databases could be related to the characteristics of the population or to differences in NVAF incidence. Other studies have reported that female patients are more prevalent than males in those older than 75 or 80 years.[45](#bcp14071-bib-0045){ref-type="ref"}, [46](#bcp14071-bib-0046){ref-type="ref"}

4.3. Baseline clinical characteristics {#bcp14071-sec-0026}
--------------------------------------

The clinical characteristics observed are comparable to similar studies which used OAC naive or non‐naive NVAF patients.[10](#bcp14071-bib-0010){ref-type="ref"}, [35](#bcp14071-bib-0035){ref-type="ref"}, [36](#bcp14071-bib-0036){ref-type="ref"} However, there is heterogeneity of the demographics and baseline characteristics across the databases. Different population coverage across the databases, as well as differences in the prevalence of cardiovascular diseases, could explain the observed differences.[37](#bcp14071-bib-0037){ref-type="ref"}

Previous cardiovascular events were the most frequent comorbidity across all databases. The observed high proportion of previous cardiovascular events in the German databases correlates with the high percentage of cardiovascular problems observed in Germany.[37](#bcp14071-bib-0037){ref-type="ref"} It might also be related to the inclusion of data from medical specialists in the German databases, whereas many of the other databases in this study consider data from general practitioners only. In addition, resource allocation for German sickness funds is based on the so‐called morbidity‐oriented risk structure compensation scheme. Therefore, all primary and secondary diagnoses must be coded to enable appropriate calculations.[47](#bcp14071-bib-0047){ref-type="ref"} The low prevalence in Mondriaan database might be because only the least critical patients received DOAC from primary care, as opposed to specialists.

The unexpectedly high proportion of CKD in the AOK and Bavarian CD populations may be explained by a higher proportion of patients with cardiovascular comorbidities or the inclusion of nonspecific codes.

4.4. Concomitant use of potentially interacting drugs {#bcp14071-sec-0027}
-----------------------------------------------------

Concomitant use of drugs has been reported to be low and in very few studies.[35](#bcp14071-bib-0035){ref-type="ref"} Concomitant treatment with other anticoagulant drugs was present in variable proportions, around 20% in the 2 German databases, and EGB. This is of concern since these patients might have a higher haemorrhagic risk. The presence of a high cardiovascular comorbidity proportion in the German databases could partly explain a higher use of medications. Furthermore, these 3 databases include reimbursed drugs from specialist prescriptions. However, some of this use could also be related to switching to anticoagulant therapy.

The concomitant use of cardiovascular drugs has been reported in some studies, in particular antiplatelet drugs, between 11 and 30% of users[12](#bcp14071-bib-0012){ref-type="ref"}, [36](#bcp14071-bib-0036){ref-type="ref"}; similarly, antiplatelet drugs were used in 10--18% of the DOAC users in several databases in our study. Amiodarone, a strong P‐glycoprotein inhibitor, was the most frequent potentially interacting drug in several databases. Lower use has been described in the OAC naïve Danish study.[36](#bcp14071-bib-0036){ref-type="ref"}

NSAIDs have been reported in similar or somewhat lower proportions in other studies.[12](#bcp14071-bib-0012){ref-type="ref"}, [35](#bcp14071-bib-0035){ref-type="ref"}, [41](#bcp14071-bib-0041){ref-type="ref"} Certain NSAIDs are available over the counter in some countries, as well as on prescription. This, together with differing prescriber behaviours treating pain or inflammatory conditions, may account for some of the observed differences.[48](#bcp14071-bib-0048){ref-type="ref"}

4.5. Dose adjustment related to age or changes in renal function {#bcp14071-sec-0028}
----------------------------------------------------------------

The proportion of dose adjustment related to age or changes in renal function was low (\<1%). However, this result should be interpreted with caution as data on renal function results were sparse (unregistered data for renal failure up to 77.9%). In fact, a study aiming to report CKD prevalence and recognition in a Swedish healthcare cohort showed that registration of CKD diagnosis was suboptimal, with only 12% of affected patients having an ICD‐10 related diagnostic code.[49](#bcp14071-bib-0049){ref-type="ref"} However, we suspect these unregistered values are more likely to reflect less severe impairment. Moreover, not all reasons for dose changes are registered in the different databases and we only considered those during the treatment episode. Therefore, patients appropriately dosed at the index date, without any further dose changes, are not considered as adjusted. The discrepancy between the proportion of patients with changes in tablet strengths and the low proportion of patients with age and CKD related adjustments might be due to patients with an increase in tablet strength not being accounted for. Other studies have reported about 20% patients receiving inappropriate doses, most often too low (38%) or excessively high dose (22%).[14](#bcp14071-bib-0014){ref-type="ref"}, [15](#bcp14071-bib-0015){ref-type="ref"}

4.6. Strengths {#bcp14071-sec-0029}
--------------

The main strength of this study is the large number of patients providing real‐world data about incidence, concomitant use of potentially interacting drugs and dose adjustments. In addition, the use of a standardized protocol across the different databases supports the interpretation and comparability of results from selected countries. Disease and drug codes were harmonized, the study results were blinded and only shared with the whole consortium after each centre had completed their analysis, avoiding some information bias and promoting independent results. The consented and broad definition of the inclusion criteria ensures the generalisability of the results as all the new users with a diagnosis of NVAF were presumably included. In addition, the performance of a sensitivity analysis excluding patients with multiple potential DOAC indications gave similar results for most of the main variables. This supports the results of the main analysis with respect to closeness to real‐life DOAC use, since several indications might be present in addition to NVAF.

4.7. Limitations {#bcp14071-sec-0030}
----------------

There was large case mix in the databases, which made comparisons between countries difficult. In addition, there are differences in population coverage among the databases. Only 1 database includes the total reference population (DNR), while others are considered representative samples of the national populations when considering age, sex and geographical distribution (UK/CPRD, Spain/BIFAP and SIDIAP, France/EGB, Mondriaan). The inclusion of nonrepresentative databases with population coverages under 90% (German databases) must be considered when extending the results to the whole population. Since we used prescription, dispensing or reimbursement data that do not have complete information on actual drug intake, there might have been certain degree of drug use misclassification, common to all clinical studies, even randomized trials. In addition, drugs prescribed by physicians, other than general practitioners, could be missed when using prescribing databases as these are commonly general practice databases.

A drop in the number of patients was observed in some databases (Figure [S1](#bcp14071-supitem-0002){ref-type="supplementary-material"}). This may be related to the fact that DOACs can be used for a variety of diagnoses. Although some patients with NVAF may have been lost in this process, the criteria ensure that we can be certain all patients included in the analysis do indeed have NVAF.

Information on the indication associated with the prescription might also be incomplete. For example, a definite linkage between compound and indication is lacking in most of the databases hence, we used the term *potential* indications. Additionally, some data sources include data from hospital admissions and contacts (DNR), while others include exclusively general practice encounters. Codes used in diagnosis were not specifically validated in this study but outcome validation has been performed in other studies showing high validity.[19](#bcp14071-bib-0019){ref-type="ref"}, [50](#bcp14071-bib-0050){ref-type="ref"}, [51](#bcp14071-bib-0051){ref-type="ref"}, [52](#bcp14071-bib-0052){ref-type="ref"}, [53](#bcp14071-bib-0053){ref-type="ref"}, [54](#bcp14071-bib-0054){ref-type="ref"}, [55](#bcp14071-bib-0055){ref-type="ref"}, [56](#bcp14071-bib-0056){ref-type="ref"}, [57](#bcp14071-bib-0057){ref-type="ref"} Laboratory values were not documented in some databases so codes for renal impairment (including somewhat nonspecific renal impairment codes) were used. This broad definition may explain the high proportion of patients with CKD found in some databases. Dose adjustment related to change in renal function and age was only assessed if a change in dose was associated with a change in renal function or in age; however, we did not assess if changes in renal function were subsequently followed by changes in dose. Moreover, a dose adjustment was defined as switching from 1 tablet strength to another of the same active substance. This definition precludes assessing posology changes that may have taken place without changing tablet strengths. Regarding potential interactions, lacking documentation of over the counter medications might be relevant, in particular for some NSAIDS, low‐dose acetylsalicylic acid (mainly pharmacodynamic interactions) and St John\'s Wort (pharmacokinetic interaction).

In conclusion, this study shows an increased incidence of use of DOACs related to NVAF in the study period across 6 European countries. In 2015, the incidence of DOAC use ranged from 8.7 per 10 000 in Spain to 27.6 per 10 000 in Denmark, with a higher incidence in men than in women, especially in patients ≥75 years. Potential use of contraindicated drugs, such as other anticoagulants, in some countries raises concerns about potential haemorrhagic risk. Finally, the proportion of dose adjustment related to changes in renal function or age deserves a more complete approach. The differences among the countries might be explained by different national or regional recommendations, prescription patterns and characteristics of the selected databases. Drug utilization studies based on several databases across different countries using a standard protocol may help to compare drug use and identify sources of variation, enabling health care decisions and supporting the rational use of medicines.
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